Zacks Investment Research downgraded shares of HTG Molecular Diagnostics (NASDAQ:HTGM) from a buy rating to a hold rating in a research report sent to investors on Friday morning.

According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “

Other research analysts also recently issued research reports about the company. Canaccord Genuity increased their price target on HTG Molecular Diagnostics to $5.00 in a research note on Friday. HC Wainwright set a $6.00 target price on HTG Molecular Diagnostics and gave the stock a buy rating in a research note on Friday. Finally, ValuEngine upgraded HTG Molecular Diagnostics from a strong sell rating to a sell rating in a research note on Monday, October 23rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. HTG Molecular Diagnostics presently has a consensus rating of Hold and an average target price of $4.88.

Shares of HTG Molecular Diagnostics (NASDAQ HTGM) traded down $0.56 during trading on Friday, hitting $3.47. The stock had a trading volume of 6,628,400 shares, compared to its average volume of 5,032,625. HTG Molecular Diagnostics has a 1 year low of $1.20 and a 1 year high of $13.25. The stock has a market cap of $42.24 and a price-to-earnings ratio of -1.36.

An institutional investor recently raised its position in HTG Molecular Diagnostics stock. Vanguard Group Inc. lifted its position in shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 38.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 135,234 shares of the medical research company’s stock after buying an additional 37,841 shares during the period. Vanguard Group Inc. owned about 1.42% of HTG Molecular Diagnostics worth $359,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 15.15% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “HTG Molecular Diagnostics (HTGM) Lowered to “Hold” at Zacks Investment Research” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/htg-molecular-diagnostics-htgm-lowered-to-hold-at-zacks-investment-research/1798648.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with Analyst Ratings Network's FREE daily email newsletter.